Safinamide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Safinamide: From Parkinson Disease to Rasmussen Subacute Encephalitis
One-Sentence Summary
Safinamide was originally used to treat Parkinson disease and related parkinsonian syndromes. The TxGNN model predicts it may be effective for Rasmussen subacute encephalitis, but there are currently 0 clinical trials and 0 publications supporting this specific prediction, so the result is a model-based hypothesis only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Parkinson disease (the Singapore licence record does not list an approved indication text; the indication comes from the knowledge graph) |
| Predicted New Indication | Rasmussen subacute encephalitis |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Safinamide is generally known as a reversible MAO-B inhibitor that also blocks voltage-gated sodium channels and reduces glutamate release. Its efficacy in Parkinson disease is established, and these properties could plausibly relate to the seizure component of Rasmussen encephalitis.
However, Rasmussen encephalitis is mainly driven by T-cell-mediated autoimmune inflammation of one brain hemisphere. Safinamide has no known immunomodulatory action, so the mechanistic link is weak and speculative. The high score (rank 5,369 in the model's ranking) is a graph-based prediction and should not be read as clinical support.
Other predicted indications (for context):
| Rank | Predicted Indication | Score | Evidence Level | Comment |
|---|---|---|---|---|
| 2 | Myelitis | 99.46% | L5 | No established role for MAO-B inhibition; speculative |
| 3 | PLA2G6-associated neurodegeneration | 99.22% | L5 | Overlapping parkinsonian features; symptomatic benefit only, if any |
| 4 | Transaldolase deficiency | 98.94% | L5 | No plausible mechanism; likely a network artifact |
| 5 | Fructose-1,6-bisphosphatase deficiency | 98.79% | L5 | No known relevance |
| 6 | Paralysis agitans, juvenile, of Hunt | 98.76% | L4 | Historical name for juvenile parkinsonism; likely overlaps with existing indications |
| 7 | Lewy body dementia | 98.43% | L4 | Plausible dopaminergic rationale; only indirect evidence |
| 8 | X-linked intellectual disability-ataxia-apraxia syndrome | 97.93% | L5 | No plausible mechanism |
| 9 | Lethal infantile mitochondrial myopathy | 97.88% | L5 | Highly speculative; no infant safety data |
| 10 | X-linked intellectual disability-cerebellar hypoplasia syndrome | 97.68% | L5 | No plausible mechanism |
Among these, Lewy body dementia and the juvenile parkinsonism entry are the most biologically coherent candidates, while the others look largely like knowledge-graph artifacts.
Literature Evidence
For the top-ranked prediction (Rasmussen subacute encephalitis), no related literature is currently available.
The only publication in the data is linked to the rank 7 prediction, Lewy body dementia:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 42623795 | 2026 | Systematic Review | Sleep Medicine | Evaluates the effectiveness and safety of drug treatments for REM sleep behaviour disorder in synucleinopathies (Parkinson disease, Parkinson disease dementia, dementia with Lewy bodies, multiple system atrophy, isolated RBD). It is indirect evidence, and the available abstract does not confirm that safinamide data were included. |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16615P | EQUFINA FILM-COATED TABLET 50MG | Tablet, film coated | Not listed in the available record |
Safety Considerations
Drug Interactions: The interaction query identified 100 potential interactions in total. The entries reviewed include:
- Major: Bupropion
- Moderate: Isometheptene, diethylpropion, phentermine, metoclopramide, rosuvastatin
- Moderate (antidiabetic agents): Chlorpropamide, glimepiride, acetohexamide, empagliflozin, nateglinide, repaglinide, and multiple insulin products (aspart, degludec, detemir, glargine, glulisine, human isophane, human regular, inhaled human)
Please refer to the package insert for warnings and contraindications, as this information was not available in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for Rasmussen subacute encephalitis rests only on a graph-based score. There are no clinical trials or publications, and the proposed mechanism is weak given the autoimmune nature of the disease. The evidence level is L5.
To proceed, the following is needed:
- Mechanism of action data for safinamide, to allow a proper mechanistic-link analysis
- Package insert warnings and contraindications from the Singapore HSA, which are required before any safety screening
- The approved indication text for the Singapore licence
- Preclinical or clinical evidence specific to Rasmussen encephalitis
- Consider prioritising Lewy body dementia, which has a more coherent dopaminergic rationale, and confirm whether the cited systematic review includes safinamide data
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.